Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand

ABSTRACT The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens. Children had a lower body weight-normalized oral clearance than adults, resulting in longer terminal elimination half-lives and higher total exposure to piperaquine (area under the concentration-time curve from 0 to 63 days [AUCday 0-63]). However, children had lower plasma concentrations in the therapeutically relevant posttreatment prophylactic period (AUCday 3-20) because of smaller body weight-normalized central volumes of distribution and shorter distribution half-lives. Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults.

[1]  F. Nosten,et al.  A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  N. Day,et al.  Development and validation of an automated solid phase extraction and liquid chromatographic method for the determination of piperaquine in urine. , 2006, Journal of pharmaceutical and biomedical analysis.

[3]  Mats O. Karlsson,et al.  Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  R. Price,et al.  Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Bergquist,et al.  Characterization of Human Urinary Metabolites of the Antimalarial Piperaquine , 2006, Drug Metabolism and Disposition.

[6]  S. Hewitt,et al.  Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. , 2002, Clinical Infectious Diseases.

[7]  C. Dolecek,et al.  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial , 2004, The Lancet.

[8]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[9]  T. Davis,et al.  Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. , 2003, British journal of clinical pharmacology.

[10]  F. Nosten,et al.  Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. , 1999, The American journal of tropical medicine and hygiene.

[11]  H. Webster,et al.  The epidemiology of malaria in a Karen population on the western border of Thailand. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  N. Day,et al.  High throughput assay for the determination of piperaquine in plasma. , 2005, Journal of pharmaceutical and biomedical analysis.

[13]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[14]  T. Davis,et al.  Effects of a High-Fat Meal on the Relative Oral Bioavailability of Piperaquine , 2005, Antimicrobial Agents and Chemotherapy.

[15]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[16]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  R. Price,et al.  Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[19]  F. Nosten,et al.  Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. , 2004, The Journal of infectious diseases.

[20]  M. Ashton,et al.  Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects , 2006, European Journal of Clinical Pharmacology.

[21]  L B Sheiner,et al.  Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.

[22]  J. Barré,et al.  Food increases the bioavailability of mefloquine , 1997, European Journal of Clinical Pharmacology.

[23]  Amin Rostami-Hodjegan,et al.  Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.

[24]  N. Day,et al.  Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.

[25]  D. Hattis,et al.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  S. Hewitt,et al.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. , 2003, British journal of clinical pharmacology.

[27]  B. Weatherley,et al.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone. , 1994, British journal of clinical pharmacology.

[28]  S. Krudsood,et al.  An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. , 2005, The Southeast Asian journal of tropical medicine and public health.

[29]  Justin J. Wilkins,et al.  NONMEMory: A run management tool for NONMEM , 2005, Comput. Methods Programs Biomed..

[30]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.